Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations

Abstract excerpt

BACKGROUND: Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous Melanoma Detection and Management
• Share to Melanoma and MAPK Pathways
• Share to NF-κB Signaling Pathways